Sutro Biopharma

Sutro Biopharma has an average 'Moderate Buy' rating from eight analysts. One holds, seven recommend buying. Average 1-year price target is $11.13. Shares opened at $1.88, with a 50-day moving average of $3.10 and a 200-day of $3.54. Institutional investors have adjusted their stakes.

Sutro Biopharma announced the selected 5.2 mg/kg dose for luveltamab tazevibulin (luvelta) in the REFRαME-O1 trial for platinum-resistant ovarian cancer, achieving a 32% objective response rate. Luvelta showed robust response rates across various folate receptor alpha (FRα) expressions, with well-managed neutropenia and no new safety concerns. The company plans an Accelerated Approval application for luvelta in mid-2027.

Luvelta demonstrated a 32% objective response rate in evaluable patients with platinum-resistant ovarian cancer at the 5.2 mg/kg dose, selected for the registrational REFRαME-O1 trial. Neutropenia was well-managed, and no new safety concerns emerged. Luvelta is positioned for an Accelerated Approval application in mid-2027.

Sutro Biopharma announced positive results from the REFRαME-O1 trial for luvelta in platinum-resistant ovarian cancer, with a 5.2 mg/kg dose achieving a 32% objective response rate and 96% disease control rate. The trial included patients with ≥25% FRα expression, potentially benefiting 8 out of 10 PROC patients. Safety profiles were manageable, with 32% Grade 3 or higher neutropenia and no febrile neutropenia. The ongoing registrational trial (Part 2) will enroll ~500 patients, randomized between luvelta and standard chemotherapy, targeting an Accelerated Approval application in mid-2027.

DelveInsight's follicular lymphoma pipeline report highlights 50+ companies developing 55+ therapies, including key players like Chia Tai Tianqing Pharmaceutical Group, Incyte Corporation, and others. Promising therapies such as Parsaclisib, TQ-B3525, and Tafasitamab are in various clinical trial phases. Notable events include Incyte's acquisition of tafasitamab rights and Janssen's collaboration with CBMG for CAR-T therapies.

Timmerman Report celebrates its 10th anniversary with events in Boston (Mar. 6) and Seattle (Mar. 13), featuring biotech leaders discussing future trends in biopharma.

Sutro Biopharma initiates REFRαME-P1 trial of Luvelta (luveltamab tazevibulin) for pediatric CBFA2T3::GLIS2 AML, aiming to assess efficacy and safety. Previously, Luvelta showed complete remission in 42% of pediatric patients with ≥5% blasts in compassionate use.

Sutro Biopharma initiates REFRαME-P1, a registration-directed study of luveltamab tazevibulin (luvelta) for pediatric patients with CBFA2T3::GLIS2 acute myeloid leukemia (AML), highlighting the potential to address unmet needs in cancer treatment.